Patients & Families

multiple myeloma

  • Multiple myeloma (MM) is a cancer of certain cells in the blood, called plasma cells.
  • The cause of MM is not known, and currently there is no cure. However, there are a number of treatment options available that can lead to remission. For some people with MM, remission can last many years.
  • Patients who have already been treated with some available therapies but continue to have progression of their disease have “relapsed” or “refractory” MM. This means that their cancer has reoccurred after they have received initial treatments.
  • Patients with relapsed/refractory MM have fewer treatment options, and more therapies that may offer these patients hope are needed.

bluebird bio clinical studies in multiple myeloma:

A phase 1 study sponsored by bluebird bio and Celgene is underway to evaluate the safety and efficacy of different doses of bb2121, an investigational CAR T cell (chimeric antigen receptor T cell) therapy, in relapsed/refractory multiple myeloma.

Celgene is also sponsoring a phase 2 clinical study of bb2121 in relapsed/refractory MM.

A separate phase 1 study sponsored by bluebird bio is underway to evaluate the safety and efficacy of different doses of bb21217, another investigational CAR T cell (chimeric antigen receptor T cell) therapy, in relapsed/refractory multiple myeloma.

To learn more about these investigational clinical studies visit clinicaltrials.gov.